Table 3 Analysis using specific thresholds for CA19-9 decline (reported results account for censored patients)

From: Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer

 

Yes

No

Log-rank χ 2

>25% decline in CA19-9?

Number of patients (%)

52 (68.4%)

24 (31.6 %)

 

Median survival (mos) (95% CI)

9.61 (8.00–11.50)

4.64 (3.45–5.82)

24.07 (df=1, P<0.001)

Median TTF (mos) (95% CI)

4.38 (3.88–6.00)

1.51 (1.00–2.76)

33.78 (df=1, P<0.001)

>50% decline in CA19-9?

Number of patients (%)

40 (52.6%)

36 (47.4%)

 

Median survival (mos) (95% CI)

10.80 (9.00–12.00)

5.82 (3.31–6.64)

14.58 (df=1, P<0.001)

Median TTF (mos) (95% CI)

4.93 (4.00–6.15)

2.07 (1.41–3.36)

26.20 (df=1, P<0.001)

>75% decline in CA19-9?

Number of patients (%)

24 (31.6%)

52 (68.4%)

 

Median survival (mos) (95% CI)

12.00 (9.21–13.59)

6.00 (5.00–6.81)

16.20 (df=1, P<0.001)

Median TTF (mos) (95% CI)

6.00 (4.87–14.50)

2.76 (1.80–3.60)

21.13 (df=1, P<0.001)

  1. CA19-9=carbohydrate antigen 19-9; CI=confidence interval; mos=months; TTF=time to treatment failure; df=degree of freedom.
Back to article page